News Releases

06/27/19CytRx Corporation Discusses Near Term Value from Out-License Deals and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com
06/26/19CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation
06/19/19CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C
05/31/19CytRx Corporation to Commence Trading on OTCQB Venture Market
05/15/19CytRx Corporation Reports First Quarter 2019 Financial Results
05/08/19CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
05/02/19CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
04/29/19CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
03/29/19CytRx Corporation Reports 2018 Financial Results
03/12/19CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems
02/13/19CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor
02/11/19CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy
02/06/19CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
01/14/19CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
12/21/18CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic
11/28/18CytRx Corporation to Present at the 11th Annual LD Micro Main Event
11/08/18CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
11/02/18CytRx Corporation Reports Third Quarter 2018 Financial Results
10/31/18Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline
10/29/18CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018
09/25/18CytRx Corporation to Present at the 2018 MicroCap Conference
09/13/18CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S
08/27/18CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018
08/06/18CytRx Corporation Reports Second Quarter 2018 Financial Results
08/01/18CytRx Corporation Pays Off Balance of Outstanding Debt
07/30/18CytRx Corporation to Hold Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018
07/25/18CytRx Announces Centurion BioPharma Corporation's Filing of a Provisional Patent Application
07/23/18CytRx Corporation Announces Expiration of Outstanding Warrants
07/16/18CytRx Corporation to Present at the Singular Research Summer Solstice 2018 Conference
06/28/18CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial
06/25/18CytRx Corporation Joins Russell Microcap® Index
06/21/18CytRx Corporation Highlights Review of NantCell Inc's Aldoxorubicin Published in Future Oncology
06/07/18CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data Presented at the American Society of Clinical Oncology 2018 Annual Meeting
06/04/18CytRx Corporation Launches Centurion BioPharma Corporation to Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates
05/30/18CytRx Corporation to Present at 8th Annual LD Micro Invitational Conference
05/17/18CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data to be Presented at the American Society of Clinical Oncology 2018 Annual Meeting
05/15/18CytRx Announces Closing of $7.0 Million Registered Direct Offering
05/11/18CytRx Announces $7.0 Million Registered Direct Offering
05/08/18CytRx Reports First Quarter 2018 Financial Results
05/07/18CytRx Corporation to Present at OneMed NYC Oncology Investor Conference 2018
05/03/18CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer
04/30/18CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Abstract Selected for Poster Presentation at the American Society of Clinical Oncology 2018 Annual Meeting
04/18/18CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting
04/09/18CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at the AACR 2018 Conference
03/19/18CytRx Reports 2017 Financial Results
03/16/18CytRx to Present at the 28th Annual Oppenheimer Healthcare Conference
03/15/18CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials
03/12/18CytRx to Hold Year End 2017 Financial Results Conference Call and Webcast on Monday, March 19, 2018
03/05/18CytRx to Present at the 30th Annual ROTH Conference
03/01/18CytRx Announces Key Addition to Corporate Development Team
02/28/18CytRx Announces Expansion of Pharma Partnering Activities for Its LADR™ Ultra-High Potency Drug Candidates
02/22/18CytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual Meeting
02/06/18CytRx Corporation to Present at the 2018 BIO CEO & Investor Conference
02/05/18CytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell Carcinoma
01/17/18CytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients with Metastatic Pancreatic Cancer
01/03/18CytRx Corporation to Present at Biotech Showcase 2018